SCHEMBL6629283

SCHEMBL6629283

COc1ccccc1CCNC(=O)c1cc2sc(Cl)cc2[nH]1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
POLB P06746 2/20 0.52
MTNR1A P48039 2/20 0.50
MTNR1B P49286 2/20 0.50
TDP1 Q9NUW8 1/20 0.48
PYGL P06737 1/20 0.48
CNR1 P21554 1/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.45
SNCA P37840 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ROCK2 O75116 1/20 0.45
ROCK1 Q13464 1/20 0.45
PKM P14618 1/20 0.45
MAPT P10636 3/20 0.45
ALDH1A1 P00352 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630820 0.82 PYGL (0.52) NPC1RAB9APOLBMTNR1AMTNR1B
SCHEMBL6630450 0.80 MTNR1A (0.49) NPC1RAB9APOLBMTNR1AMTNR1B
SCHEMBL2106190 0.78 MEN1 (0.52) NPC1RAB9APOLBMTNR1AMTNR1B
SCHEMBL6632773 0.77 CNR1 (0.50) NPC1RAB9APOLBPYGLCNR1
SCHEMBL6631318 0.76 NPC1 (0.53) NPC1RAB9APYGLHPGDSNCA
SCHEMBL6633192 0.76 NPC1 (0.51) NPC1RAB9APOLBMTNR1AMTNR1B
SCHEMBL6630432 0.73 PYGL (0.48) NPC1RAB9APOLBMTNR1AMTNR1B
SCHEMBL6631149 0.73 PYGL (0.48) NPC1RAB9APOLBMTNR1AMTNR1B
SCHEMBL6630885 0.72 PYGL (0.52) PYGLSMN1; SMN2ALDH1A1KDM4E
SCHEMBL6631621 0.72 PYGL (0.53) NPC1RAB9APYGLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317459-B1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2004-04-07 EP claimed
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2003-12-18 US claimed
EP-1317459-B1 BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS ASTRAZENECA AB (SE) 2004-04-07 EP disclosed
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors ASTRAZENECA AB (SE) 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232875-A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors GYS1, GYS2, PYGL NPC1 3131/4885RAB9A 3130/4885POLB 1166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.